Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,189
datasets available to search
ShareScore release 0.9.0
Dataset results
2,189 results for “AML”
A Study to Evaluate the Tolerance and Efficacy of Mitoxantrone Hydrochloride Liposome Injection Combined With Cytarabine in Patients With Acute Myeloid Leukemia (AML)
ClinicalTrials.gov study NCT05100303. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Natural Killer(NK) Cell Therapy for AML Minimal Residual Disease
ClinicalTrials.gov study NCT05601830. IPD Sharing: NO. Countries: 1. Publications: 0.
Trial to Find and Investigate a Safe Dose of F16IL2 and BI 836858 in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation
ClinicalTrials.gov study NCT03207191. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML)
ClinicalTrials.gov study NCT02892318. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS
ClinicalTrials.gov study NCT02923986. IPD Sharing: NO. Countries: 1. Publications: 0.
A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)
ClinicalTrials.gov study NCT05190471. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Bisantrene Combination for Resistant AML
ClinicalTrials.gov study NCT04989335. IPD Sharing: Not stated. Countries: 1. Publications: 0.
High-Dose Imatinib for Relapsed/Refractory c-Kit Positive Acute Myelogenous Leukemia (AML)
ClinicalTrials.gov study NCT00707408. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Study to Evaluate and Compare the Efficacy and Safety of AZM and AML Combined and Alone in Mild-to-moderate Essential Hypertensive Subjects
ClinicalTrials.gov study NCT05385770. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Vyxeos® With Clofarabine for Pediatric AML
ClinicalTrials.gov study NCT07156435. IPD Sharing: YES. Countries: 6. Publications: 0.
Epidemiological Study of a Prospective Cohort of Patients Aged 60 and Over Managed for Acute Myeloid Leukemia (AML) and Receiving Intensive Induction Therapy
ClinicalTrials.gov study NCT06891144. IPD Sharing: NO. Countries: 1. Publications: 0.
Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic Malignancies
ClinicalTrials.gov study NCT00697671. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML
ClinicalTrials.gov study NCT05305859. IPD Sharing: NO. Countries: 1. Publications: 0.
Combination of 5-azacitidine and Lenalidomide in Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Myelodysplastic Syndromes
ClinicalTrials.gov study NCT00923234. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML
ClinicalTrials.gov study NCT04501120. IPD Sharing: Not stated. Countries: 1. Publications: 0.
T-cell Depleted Donor Lymphocyte Infusion (DLI)for Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)
ClinicalTrials.gov study NCT00242515. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Sulindac for Patients With AML
ClinicalTrials.gov study NCT01843179. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Phase II Study of Clofarabine in Pediatric Acute Myelogenous Leukemia (AML) Patients
ClinicalTrials.gov study NCT00042354. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Panobinostat Maintenance After HSCT fo High-risk AML and MDS
ClinicalTrials.gov study NCT04326764. IPD Sharing: Not stated. Countries: 2. Publications: 0.
RFC and MTHFR SNPs & hENT1- dCK Expression as Prognostic Factors in ALL & hENT1- dCK Expression as Prognostic Factors in AML
ClinicalTrials.gov study NCT01307241. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.